Clinical trial
Impact of Eslicarbazepine Acetate on Lipid Metabolism and Cardiovascular Risk Factors
NCT02573272 is registered in ClinicalTrials.gov with Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Impact of Eslicarbazepine Acetate on Lipid Metabolism and Cardiovascular Risk Factors
- Lead sponsor
- Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- June 30, 2015
- Completion date
- October 31, 2016
- Enrollment
- 204 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.